elicits systemic inflammatory responses that include the stimulation of bone marrow and progression of atherosclerosis. The present study was designed to assess the effect of repeated exposure of PM10 on the turnover and release of polymorphonuclear leukocytes (PMNs) from the bone marrow into the circulation and the effect of lovastatin on the PM10-induced bone marrow stimulation. Rabbits exposed to PM10 three times a week for 3 wk, were given a bolus of 5=-bromo-2=-deoxyuridine to label dividing cells in the marrow to calculate the transit time of PMNs in the mitotic or postmitotic pool. PM10 exposure accelerated the turnover of PMNs by shortening their transit time through the marrow (64.8 Ϯ 1.9 h vs. 34.3 Ϯ 7.4 h, P Ͻ 0.001, control vs. PM10). This was predominantly due to a rapid transit of PMNs through the postmitotic pool (47.9 Ϯ 0.7 h vs. 21.3 Ϯ 4.3 h, P Ͻ 0.001, control vs. PM10) but not through the mitotic pool. Lovastatin delayed the transit time of postmitotic PMNs (38.2 Ϯ 0.5 h, P Ͻ 0.001 vs. PM10) and shifted the postmitotic PMN release peak from 30 h to 48 h. PM10 exposure induced the prolonged retention of newly released PMNs in the lung, which was reduced by lovastatin (P Ͻ 0.01). PM10 exposure increased plasma interleukin-6 levels with significant reduction by lovastatin (P Ͻ 0.01). We conclude that lovastatin downregulates the PM10-induced overactive bone marrow by attenuating PM10-induced systemic inflammatory responses. polymorphonuclear leukocytes; interleukin-6 MANY WELL-DOCUMENTED STUDIES have supported the concept that ambient particulate matter (particles less than 10 m or PM 10 ) exposure induces systemic inflammatory responses, characterized by an increase in circulating proinflammatory mediators (10, 22) and blood elements such as leukocytes (8, 16) or platelets (18). These systemic responses to PM 10 exposure have been implicated in the risk for downstream cardiovascular events (4). The mechanisms underlying these systemic inflammatory responses remain unclear, but the "spillover" of lung inflammatory mediators into the systemic circulation has the most experimental support (9, 10, 22, 28). Exposure to PM 10 elicits a brisk pulmonary inflammatory response (22) and local production of proinflammatory cytokines such as interleukin (IL)-6 that translocate into the systemic circulation (10), whereby stimulating the bone marrow to promote the release of leukocytes and platelets (6, 8, 15, 16) and activating the vascular endothelial cells to instigate adverse cardiovascular events (4).
MANY WELL-DOCUMENTED STUDIES have supported the concept that ambient particulate matter (particles less than 10 m or PM 10 ) exposure induces systemic inflammatory responses, characterized by an increase in circulating proinflammatory mediators (10, 22) and blood elements such as leukocytes (8, 16) or platelets (18) . These systemic responses to PM 10 exposure have been implicated in the risk for downstream cardiovascular events (4) . The mechanisms underlying these systemic inflammatory responses remain unclear, but the "spillover" of lung inflammatory mediators into the systemic circulation has the most experimental support (9, 10, 22, 28) . Exposure to PM 10 elicits a brisk pulmonary inflammatory response (22) and local production of proinflammatory cytokines such as interleukin (IL)-6 that translocate into the systemic circulation (10) , whereby stimulating the bone marrow to promote the release of leukocytes and platelets (6, 8, 15, 16) and activating the vascular endothelial cells to instigate adverse cardiovascular events (4) .
We have previously shown that exposure to PM 10 stimulates the turnover of polymorphonuclear leukocytes (PMNs) in the bone marrow and accelerates their release into the circulation (6, 15, 16) . The release of PMNs from the bone marrow can be stimulated by several mediators including granulocyte macrophage colony-stimulating factor (GM-CSF) (13) , , and IL-8 (24) , all of which have been indicated as the mediators induced by PM 10 exposure (19, 28) . These newly released PMNs have distinct behavioral and inflammatory properties, leading to their enhanced potential to sequester in the lung capillaries (25, 28, 31) and mediate vascular endothelial damage (29, 30) . Therefore, the downregulation of an overactive bone marrow could be an important strategy to reduce adverse respiratory and vascular effects of PM 10 exposure.
Studies from our laboratory recently showed that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) suppress the local production of proinflammatory cytokines in the lung as well as the recruitment of PMNs into the lung tissues following PM 10 exposure (14) . Statins are known to possess myelosuppressive effects (1); therefore, here we postulate that statins will dampen the bone marrow stimulation induced by PM 10 exposure. The present study was designed to determine the effects of statins on the bone marrow of rabbits exposed to PM 10 (EHC-93). We used a well-established rabbit model of PM 10 exposure for 3 wk (6, 16, 22) and determined the bone marrow response by using thymidine analog, 5=-bromo-2=-deoxyuridine (BrdU) to label the dividing myeloid cells in the bone marrow. BrdU labeling enables morphological differentiation to quantify newly released PMNs from the bone marrow. In this study, we investigated the kinetics of BrdU-labeled PMNs in the circulation to estimate the transit time of myeloid cells through the bone marrow as well as the size of the different pools of PMNs in the marrow. In addition, we determined the retention of BrdUlabeled PMNs (newly released PMNs) in the lung tissues following PM 10 exposure.
MATERIALS AND METHODS
Urban air particulate. Urban air PM10 (EHC-93) was obtained from Environmental Health Directorate, Health Canada (Ottawa, ON, Canada). The detailed characteristics of EHC-93, including particle preparation and chemical composition, have been described elsewhere (32) . Briefly, EHC-93 particles have a median diameter of 0.8 Ϯ 0.4 m (median Ϯ SD), consist of 99% (in number, not mass) of particles Ͻ 3.0 m, and were collected over a major North American city in 1993. Like most ambient particulate matter, it contains a complex mixture of inorganics (e.g., sulfates, nitrates), a carbonaceous core, and 26 different metals with organic components. It has previously been shown to induce lung inflammation and endothelial dysfunction (22) . The endotoxin content in EHC-93 is small (6.4 Ϯ 1.8 EU/ml or Ͻ 3.0 ng/ml) and has been shown to cause neither a local nor a systemic inflammatory response per se when instilled into the rabbit lungs (33) .
Experimental animals. Female New Zealand White (NZW) rabbits (n ϭ 24; weight, 2.6 Ϯ 0.1 kg; Charles River Laboratories, Montreal, QC, Canada) were used in this study. All animals were 12 wk old at the start of the experimental protocol. They were housed in a clean-air and viral-free room with restricted access, given a standard rabbit diet and water ad libitum. The protocol was approved by the Animal Experimentation Committee of the University of British Columbia.
Experimental design. The animals were assigned randomly into four experimental groups (each group, n ϭ 6): 1) saline instillation, 2) saline instillation with lovastatin treatment, 3) PM 10 instillation, and 4) PM10 instillation with lovastatin treatment. Either PM10 or saline was administrated by a direct intratracheal instillation method, three times a week (the first, second, third are 48 h apart, and the fourth is 72 h after the third in the following week) for 4 wk. PM 10 particles (1.0 mg/kg) were suspended in 750 l of normal (0.9%) saline solution and sonicated for 60 s just before each instillation. The animals were anesthetized with 20 mg/kg ketamine and 5 mg/kg xylazine by a single intramuscular injection assisted by 0.25% isofluorane when necessary. A 3.0-mm ID uncuffed endotracheal tube was placed into the trachea by a blind technique. Proper placement of the endotracheal tube was confirmed by a cough reflex, the respiratory sounds and to-and-fro condensation inside the tube. Once properly intubated, either PM 10 suspension (750 l) or saline (750 l) was administrated via a MicroSprayer (Dry Powder Insufflator, Model DP-4; Penn-Century, Wyndmoor, PA), cannulated through the endotracheal tube. This method ensures an aerosol and accurate dosing of PM 10 . The relevance of the PM10 dose (1.0 mg/kg) has been validated previously in the same rabbit model (16) . Briefly, we have estimated that 40% of the delivered dose is aspirated into the lung by the direct intratracheal instillation, with Ͻ4% of which reaching the alveolar surface. Assuming a 5.8-m 2 alveolar surface area for a 2.6-kg rabbit, we calculated the alveolar exposure of 3.1 ng/cm 2 for each dose or 24.8 ng/cm 2 throughout the study period. This exposure is estimated to be equivalent with humans exposed to 150 g/m 3 of EHC-93 for 20 days, which is equivalent with exposure of humans during the Southeast Asia forest fires in 1997 (23) .
Lovastatin (Toronto Research Chemicals, Toronto, ON, Canada) treatment was given orally at a dosage of 5 mg/kg per day for 8 wk, beginning 4 wk before the PM 10/saline exposure. Lovastatin dose (5 mg/kg per day) was selected as the lowest effective dose reported in an experimental model using lovastatin for NZW rabbits (20) . Lovastatin treatment was given in small volume (2-3 g) of food mixture (cookie dough) that contained the required amount of lovastatin. Complete consumption of the drug-containing food mixture was confirmed on a daily basis. The length of statin treatment (4 wk before PM 10 exposure and an additional 4 wk during PM10 exposure) was decided based on our preliminary study, in which statins were given for different periods (1, 2, 3, and 4 wk) and the effects of statins became increasing more evident over the time course (data not shown). Four hours after the final (12th) exposure, rabbits were euthanized with an overdose of pentobarbital sodium.
Blood samples. To label dividing cells in the bone marrow, 100 mg/kg of BrdU (Sigma-Aldrich, St. Louis, MO) was administered 24 h before the ninth instillation by infusion through the marginal ear vein at a concentration of 10 mg/ml in normal sterile saline over a period of 15 min (7, 16, 26) . One ear was thoroughly shaved, and a 20G Teflon catheter (Angiocath; BD, Franklin Lakes, NJ) was inserted into the central ear artery for the following serial blood samplings. The catheter was flushed with 50 -100 l of heparin (1,000 U/ml), closed with a plastic luer-lok cap and held in place with Beiersdorf Leukoplast adhesive tape. Blood samples (1.5 ml at a time) were obtained just before the ninth instillation (baseline) and at 4, 8, 12, 16, 20, 24, 30, 36, 48, 72, 96, 120, 144 , and 168 h after the ninth instillation. No sedative agents were required to collect blood from the indwelling 20G catheter, and towel restraint provided warmth and comfort to the rabbit. Blood (0.5 ml) was collected in tubes containing ethylenediaminetetraacetic acid (Vacutainer no. 366643; BD Biosciences) for leukocyte counts and cytokine analyses, and 1 ml was collected in tubes containing acid-citrate dextrose (ACD) (Vacutainer no. 364606; BD Biosciences) for the detection of BrdU-labeled PMNs (PMN BrdU ). White blood cell counts were determined on Abbott Cell Dyn 3700 (Abbott Laboratories, Abbott Park, IL). Differential counts were obtained by Wright's stained blood smears, and 100 PMNs were evaluated in randomly selected fields of view to determine the changes in the number of band cells. Blood collected in ACD tubes was processed to obtain leukocyte-rich plasma (LRP). Erythrocytes were allowed to sediment for 25-30 min after the addition of an equal volume of 4% dextran (average molecular weight, 162,000; SigmaAldrich) in PMN buffer. The resulting LRP was cytospun onto 3-aminopropryl-triethoxysilane-coated slides by cytocentrifugation (150 l, 500 rpm, 5 min; Cytospin 4; Thermo Shandon, Pittsburgh, PA) at room temperature. The cytospun specimens were air dried, fixed in acetone for 10 min, and stored at Ϫ80°C for subsequent immunohistochemical analyses.
Immunohistochemical detection of PMN BrdU cells in the circulation. The cytospun specimens were stained for the presence of nuclear BrdU by using the dextran polymer conjugate two-step visualization system (K5355, Envision G 2 System/AP; DakoCytomation, Glostrup, Denmark) according to the manufacturer's instructions. Briefly, the slides were digested at room temperature for 5 min in a 0.08% pepsin solution acidified to pH 2.5. DNA in the samples was denatured in 2N HCl at room temperature for 10 min. The 2N HCl was neutralized by washing the slides three times with 0.1 M borate buffer, pH 8.5, each for 5 min. After nonspecific antigen blocking (Protein Block Serum-Free; Dako, ON, Canada) for 10 min, the specimens were incubated with 2.62 mg/l (1:100 dilution) monoclonal mouse anti-BrdU antibody (Clone Bu20a; Dako) for 30 min in a humidity chamber at room temperature. Nonspecific mouse immunoglobulin G (5 mg/ml) was used as a negative control. The slides were washed with Tris-buffered saline with Tween-20 and then incubated with anti-mouse secondary antibody conjugated with a Dextran backbone of a large number of alkaline phosphatase (AP) molecules for 30 min. AP-labeled amplification polymers were added for 30 min to further enhance the AP complex, and the reactions were visualized by red chromogen. The slides were counterstained with Gill hematoxylin.
Evaluation of PMN BrdU in the circulation. PMN BrdU were evaluated as previously described in detail (26) . Briefly, PMNs with any nuclear stain were counted as BrdU-labeled PMNs. PMN BrdU were divided into three groups according to the intensity of nuclear staining, using an arbitrarily designated grading system, weakly positive (staining of less than 5% of the nucleus: G1), moderate positive (staining of 5 to 80% of the nucleus: G2), and highly positive (staining of more than 80% of the nucleus: G3). This grading system was designed to evaluate the transit time of the myeloid cells that were in their last division in the mitotic pool when exposed to BrdU (G3), those that were in the middle (G2), and those that were in their first division (G1). PMNs exist in the marrow in two divisions: 1) the proliferative or mitotic pool (myeloblasts, promyelocytes, myelocytes) and 2) the maturation storage or postmitotic pool (metamyelocytes, bands, mature neutrophils, polymorphonuclear leukocytes); therefore, G1 and G3 cells represent the mitotic and postmitotic pool, respectively. All the slides were scanned, and their images were captured with the Aperio ScanScope XT (Aperio Technologies, Vista, CA). The coded images were analyzed using Image Pro Plus (Media Cybernetics, Bethesda, MD) without knowledge of the group or sampling time. Fields were selected in a systematic randomized fashion, and 200 cells were evaluated per specimen.
PMN transit time from bone marrow to circulation. Transit time of PMN BrdU through the bone marrow was calculated as previously described (26) . Briefly, the number of PMN BrdU was corrected for the disappearance (t 1/2) of cells in the circulation. In previous studies, we have reported that the half-life (t 1/2) of PMN BrdU in rabbits is 270 min or 4.5 h, using a whole blood transfusion method (3) . We have applied this rate of exponential loss of PMN BrdU from the circulation to calculate the number of PMN BrdU released from the bone marrow and the transit time through the different pools of the bone marrow in the following manner:
where N is the relative number of labeled cells; ti and tj are the initial and successive time; ⌬t ϭ tj -ti; and k ϭ ln2/t1/2.
These calculations were made for each blood collection interval, and a histogram was drawn showing the distribution of the PMN Cytokine analyses. Plasma IL-6 levels were analyzed by enzymelinked immunosorbent assay (ELISA) using commercially available kits (CSB-E06903RB; Cusabio Biotech, Beijing, China) according to the manufacturer's instructions. Each sample was measured in duplicate.
Immunohistochemical detection of PMN BrdU cells in the lung tissue. After euthanasia, the chest was opened rapidly, the base of the heart was ligated, and the right lung was inflated at 25 cmH2O by intratracheal instillation of 4% paraformaldehyde. After full inflation, the right main bronchus was ligated and resected from the trachea. The right lung was separated into the four lobes (cranial, middle, caudal, and accessory) and fixed in 4% paraformaldehyde for 24 h. The sliced lung tissues were embedded in paraffin, sectioned 4 m thick, and mounted on glass slides. After deparaffinization and rehydration, the presence of nuclear BrdU was examined by the same immunostaining method as described above except for the dilution factor of primary antibody, in which 1:300 dilution (0.87 mg/l) was used for the lung tissues.
Evaluation of PMN BrdU in the lung. At least five serial cuts from each lobe were stained, scanned with the Aperio ScanScope XT, evaluated for quantitative analysis, and then averaged per animal. To evaluate BrdU-positive staining nuclei of PMNs, the area of positive staining was accurately measured by a color image analyzer (Image Pro-Plus 5.0; Media Cybernetics). Each lung crosssection was captured at ϫ320 magnification, and color segmentation was employed to determine the area (in m 2 ) that was stained red (positive staining) in PMNs. The area of analysis was manually traced with Image Pro-Plus 5.0, which allowed the areas of positive staining to be calculated as a percentage of the overall nuclear size of PMN BrdU compared with the whole area of a given field of view. Ten randomly selected fields from each lobe were analyzed so that 40 fields per animal were analyzed. In all the quantitative analyses, the images were processed by the investigators (R.M. and N.B.) unaware of treatment group assignments. Intra-and interobserver variability were less than 5% for all measurements.
Statistics. Values are expressed as means Ϯ SE. The repeatedmeasure variables were analyzed using a mixed-model repeatedmeasures ANOVA with two between-subject factors (PM10 exposure and lovastatin treatment) and one within-subject factor (time after PM10 exposure) for each dependent variable. To confirm the contribution of PM10 or lovastatin in the repeated-measures variables, a mixed-model repeated-measures ANOVA on a selected set of analysis intervals was performed as appropriate. The transit time of PMN BrdU , the volume fractions of PMN BrdU in the lung, and average cytokine levels were compared by two-way factorial ANOVA with PM10 exposure and lovastatin treatment as independent variables, followed by Bonferroni's post hoc test. Transcripts with a significant PM 10 exposure ϫ statin treatment interaction (P Ͻ 0.05) were additionally analyzed with a one-way ANOVA followed by Newman-Keuls post hoc test for pairwise comparisons. Statistical significance was considered at P Ͻ 0.05 (two-tailed).
RESULTS
Leukocytes in the circulation. The kinetics of leukocytes after PM 10 /saline intratracheal instillation was characterized by an initial drop, followed by a compensatory increase. For the total circulating white cell counts, the compensatory increase was observed for ϳ20 h, followed by a smaller second drop and the second compensatory increase (a biphasic response; Fig. 1A ). PM 10 exposure contributed to consistent reduction in circulating leukocytes (PM 10 main effect, P Ͻ 0.01), and lovastatin gradually improved PM 10 -induced leukopenia at later time points with significant lovastatin main effect after 24 h (P Ͻ 0.05). The kinetics of PMNs was also biphasic in nature (Fig. 1B) . PM 10 exposure suppressed circulating PMNs (PM 10 main effect, P Ͻ 0.01), and lovastatin improved this neutropenia. The effect of lovastatin was more evident at later time points with a significant lovastatin main effect after 12 h (P Ͻ 0.05). In contrast, PM 10 exposure strongly promoted the band cell influx into the systemic circulation (PM 10 main effect, P Ͻ 0.01; Fig. 1C ). Band cell counts peaked at 12 h after PM 10 exposure, whereas lovastatin delayed the peak to 24 h. The effect of lovastatin was observed at earlier time points (20 h and before, lovastatin main effect, P Ͻ 0.01), but not at later time points.
Effect of statins on plasma IL-6 levels. The mean IL-6 level (averaged from blood samples collected at intervals of 4 h to 96 h) was increased after PM 10 exposure (P Ͻ 0.05; Fig. 2A ) and significantly downregulated to saline control levels by lovastatin (P Ͻ 0.01). The IL-6 levels after PM 10 exposure quickly reached their peak at 4 h and stayed high for more than 20 h. By contrast, the IL-6 levels of the saline group reached their peak at 20 h and attenuated rapidly. As was in band cells, the effect of lovastatin was observed at earlier time points (20 h and before, lovastatin main effect, P Ͻ 0.01) but not at later time points (Fig. 2B) .
Effect of statins on the release of PMNs from the bone marrow. The release of PMN BrdU after PM 10 exposure showed two peaks, the first peak at 24 h and the second at 72 h, whereas the saline group showed only one peak at 72 h (Fig. 3A) , indicating an early-phase response of the bone marrow to PM 10 exposure (PM 10 main effect, P Ͻ 0.01). This acute response was attenuated by lovastatin (lovastatin main effect, P Ͻ 0.05). The peak at 72 h was blunted by lovastatin, and the decline after the peak was slower, showing a moderate amount of PMN BrdU even at 144 h. The release of BrdU-labeled G1 cells (the mitotic pool; G1 BrdU ) reached their peak at 96 h for the saline group, whereas PM 10 exposure accelerated the release to shift the peak to 72 h (PM 10 main effect, P Ͻ0.01; Fig. 3B ). The peak for the PM 10 ϩ lovastatin group was blunted, peaking between 72 and 120 h (lovastatin main effect, P Ͻ 0.05). The kinetics of BrdU-labeled G3 cells (the postmitotic pool; G3 BrdU ; Fig. 3C ) showed a significant early increase in the release of G3 BrdU cells induced by PM 10 (PM 10 main effect, P Ͻ 0.001). This early G3 response contributed substantially to the first PMN BrdU peak shown at 24 h. The effect of lovastatin on the early G3 response was also significant (lovastatin main effect, P Ͻ 0.05).
To evaluate the effect of PM 10 and lovastatin on the size of the bone marrow pools, the cumulative number of PMN BrdU in the circulation was calculated as described previously (27) . Figure 4 shows the cumulative frequency distribution of all BrdU-labeled PMNs, G1 cells, and G3 cells. PM 10 exposure accelerated the accumulation of PMN BrdU , and lovastatin attenuated the accumulation (PM 10 main effect, P Ͻ 0.01; lovastatin main effect, P Ͻ 0.05; Fig. 4A ). PM 10 exposure also accelerated the accumulation of G1 BrdU (the mitotic pool; PM 10 main effect, P Ͻ0.01; Fig. 4B ) that was suppressed by lovastatin with the main effect between 48 h and 120 h (lovastatin main effect, P Ͻ 0.01). The effect of PM 10 exposure on the accumulation of G3 BrdU (the postmitotic pool) was more rapid and observed before 48 h (PM 10 main effect, P Ͻ 0.001), and this accumulation was strongly suppressed by lovastatin (lovastatin main effect, P Ͻ 0.001 before 48 h; Fig. 4C ).
Transit time of PMNs through the bone marrow. Fig. 2 . A: average plasma IL-6 levels within 96 h following direct intratracheal instillation of either PM10 or saline Ϯ lovastatin treatment. PM10 exposure significantly increased plasma IL-6 levels with significant downregulation by lovastatin. B: changes in plasma IL-6 levels after the 9th PM10/saline instillation following exposure to PM10 (gray circles; n ϭ 6), PM10 with lovastatin (closed circles; n ϭ 6), or saline (control; open circles; n ϭ 6) for 3 wk. PM10 exposure showed no main effect, whereas lovastatin showed a significant main effect at early time points (20 h and before, ##P Ͻ 0.01). Fig. 1 . Circulating white blood cell (WBC) counts (A), polymorphonuclear leukocyte (PMN) counts (B), and band cell counts (C). Rabbits were exposed to ambient particulate matter (PM10) (gray circles; n ϭ 6), PM10 with lovastatin (closed circles; n ϭ 6), or saline (control; open circles; n ϭ 6) for 3 wk. The kinetics of WBC/PMN was characterized as biphasic waveforms, possibly indicating repeated cycles of marginalization into the lung and compensatory bone marrow response. PM10 exposure caused persistent leukopenia and neutropenia, both of which were improved by lovastatin, especially at later time points (after 24 h for WBC or 12 h for PMN). By contrast, PM10 exposure strongly stimulated the release of band cells with significant reduction by lovastatin at earlier time points (20 h and before). **P Ͻ 0.01, PM10 main effect; ##P Ͻ 0.01, lovastatin main effect; #P Ͻ 0.05, lovastatin main effect.
time for the postmitotic pool (P Ͻ 0.001) but not for all PMN BrdU or the mitotic pool.
Sequestration of PMN
BrdU in the lung. To determine whether these newly released PMNs (PMN BrdU ) are retained in the lung tissues, we harvested lung tissues 7 days after BrdU injection and immunostained with anti-BrdU antibodies to detect PMN BrdU in the lung (Fig. 5A) . Most PMN BrdU were band cells with highly positive nuclear stain or the G3 pattern (i.e., PMNs from the postmitotic pool). A greater number of PMN BrdU was observed in the lung tissues exposed to PM 10 (P Ͻ 0.01; Fig.  5B ). Lovastatin abolished this increase (P Ͻ 0.01) and promoted the clearance of these immature PMNs from the lung.
DISCUSSION
Consistent with the observations from our previous studies, the present study showed that exposure to ambient PM 10 particles induces systemic inflammatory responses characterized by an increase in systemic proinflammatory mediators such as IL-6 (22) . PM 10 exposure also stimulates the bone marrow to accelerate the turnover (differentiation) and release Fig. 4 . Cumulative number of BrdU-labeled PMNs (A), G1 cells (B), and G3 cells (C) in the circulation. Rabbits were exposed to PM10 (gray circles; n ϭ 6), PM10 with lovastatin (closed circles; n ϭ 6), or saline (control; open circles; n ϭ 6) for 3 wk. PM10 exposure accelerated the accumulation of PMN BrdU , G1 BrdU , and G3 BrdU , and lovastatin attenuated the accumulation of G1 BrdU at later time points, and G3
BrdU at earlier time points. ***P Ͻ 0.001, PM10 main effect; **P Ͻ 0.01, PM10 main effect; ###P Ͻ 0.001, PM10 lovastatin main effect; ##P Ͻ 0.01, lovastatin main effect; #P Ͻ 0.05, lovastatin main effect. BrdU ; C) in percentages into the circulation. Rabbits were exposed to PM10 (gray circles; n ϭ 6), PM10 with lovastatin (closed circles; n ϭ 6), or saline (control; open circles; n ϭ 6) for 3 wk. A: PM10 exposure stimulated the release of PMNs showing 2 peaks, the first at 24 h and the second at 72 h. Lovastatin attenuated the early response at 24 h, and the peak at 72 h was blunted (lovastatin main effect, P Ͻ 0.05). B: PM10 exposure shifted the peak of G1 BrdU release from 96 h to 72 h. Lovastatin blunted the peak showing a modest increase kept between 72 h and 144 h (lovastatin main effect, P Ͻ 0.05). C: PM10 exposure accelerated G3 BrdU release to peak at 24 h, and lovastatin decelerated the release to peak at 48 h (lovastatin main effect, P Ͻ 0.05). ***P Ͻ 0.001, PM10 main effect; **P Ͻ 0.01, PM10 main effect; #P Ͻ 0.05, lovastatin main effect.
of PMNs (16) . This study extends these observations by showing that statins (lovastatin) dampen these systemic responses by decreasing the levels of PM 10 -induced circulating mediators (IL-6), thereby suppressing the bone marrow stimulation. The effect of statins was predominantly on PMNs in the postmitotic pool (G3 BrdU ) as evidenced by marked delay in the transit time of G3
BrdU and a decrease in the release of G3 BrdU . Interestingly, statins also reduce the retention of these newly released PMNs in the lung tissues. These novel pleiotropic effects of statins provide some new insight in their anti-inflammatory properties, indicating that this class of drugs could be beneficial to reduce the adverse cardiovascular effects by air pollution exposure. In addition, this study indicates that statin use should be considered a variable that might affect results of epidemiological studies of particle health effects. Lastly, our pilot data showed that a shorter period of statin pretreatment has less impact on the systemic inflammatory response, suggesting that acute statin treatment during highpollution episodes may not be beneficial, although this awaits direct experimental demonstration.
In this study, the thymidine analog BrdU was used to label dividing PMNs in the marrow that allows us to monitor the intravascular kinetics and tissue distribution of the PMNs newly released from the bone marrow. This approach takes full advantage of animal models because BrdU administration should be avoided for humans due to its acute toxicity, teratogenicity, and carcinogenicity. Using this technique, we have previously shown that repeated PM 10 exposure promotes the local (lung) production of proinflammatory mediators such as IL-6 and GM-CSF, which translocate into the systemic circulation to cause downstream bone marrow stimulation that accelerates the turnover of both monocytes and PMNs in the postmitotic pool of the marrow (6, 15, 16) . In these previous studies using the same rabbit model, we observed that repeated PM 10 exposure shortens the transit time of postmitotic PMNs, but not that of all PMNs (15) , which contrasts our findings herein showing the effects of PM 10 exposure on transit time for both all and postmitotic PMNs (Table 1) . Our PM 10 exposure protocol was slightly modified in the present experiments from biweekly (6) to triweekly but keeping the dose of PM 10 for each instillation at the same amount. As a result, we assessed the kinetics of PMNs after the ninth instillation, instead of the sixth (as was in the previous studies), which might be implicated in the dose-dependent nature of PM 10 -induced bone marrow stimulation. Moreover, the instillation method was also improved by a microsprayer that allows even peripheral distribution of PM 10 particles. We suspect that our present exposure protocol reflects more real-life exposure, and our data suggest that this protocol is more stimulative for the bone marrow.
The mechanisms underlying the myelosuppressive effects of statins are unclear. It is known that statins possess wellestablished anti-inflammatory properties including an ability to reduce proinflammatory cytokines such as IL-1, IL-6, IL-8, and GM-CSF from several cell types (14, 19) , all of which are known to stimulate the differentiation of neutrophilic cell line. Among others, IL-6 is a multifunctional cytokine that plays a key role in neutropoiesis (21) . We showed herein that statins suppress plasma IL-6 levels following PM 10 exposure at early time points (ϳ20 h), and their effect tapered off with time (Fig.  2B) . Statins also delay the transit time of PMNs in the postmitotic pool, with little or no effect on the mitotic pool (Table  1 ), a differential effect that might reflect their downregulation of IL-6 predominantly at early time points. Likewise, PM 10 exposure increased the pool size of all PMN BrdU at early time points (Fig. 4A) , which was predominantly due to a significant increase in the release of PMNs from the postmitotic pool (Fig.  4C) . Again, statins showed their strong inhibitory effects against this early increase. We have previously shown that IL-6 produced in the lung following PM 10 exposure translocates into the circulation within 4 h (10), and we suspect that this early release of the cytokine into the bloodstream is responsible for activating the marrow, thereby promoting the release of PMNs. Collectively, these data suggest that the regulation of IL-6 by statins is likely to contribute to indirect deactivation of the bone marrow, thereby downregulating neutropoiesis as well as neutrophil kinetics. In addition, there is a growing number of reports that have indicated the antitumor effects of statins (2, 5, 17) , and it is possible that statins have a similar direct suppressive effect on hematopoietic cells via the same mechanisms as other antitumor agents. However, the molecular mechanism of the antitumor properties of statins is an area of active research and still yet to be identified.
Exposure to PM 10 also promotes PMN retention in the lung tissues (Fig. 5B) . Studies from our laboratory have shown that PM 10 exposure accelerates the release of immature PMNs from the bone marrow (6, 8, 15, 16) , and these immature PMNs sequester preferentially in pulmonary capillaries (11, 29) and migrate less efficiently into the tissues (29, 30) , both indicating their greater potential to induce lung injury. This study demonstrated that these newly released immature PMNs remain in the lung tissues for a prolonged period of time (Fig. 5B) . We have recently showed that statins reduce lung inflammation induced by PM 10 exposure (14) , and here we showed that statins promote the clearance of these retained PMNs from the lung tissues that might contribute to, at least in part, their anti-inflammatory property against PM 10 exposure in the lung.
Possible factors that could impact the bone marrow transit times are the multiple blood samplings taken over the 7-day experimental period. Although the blood volume at each collection is small (1.5 ml ϭ 1% of the total blood volume), the total volume over the 7 days is more substantial (22.5 ml ϭ 15% of the total blood volume). Hematopoietic growth factors that stimulate the bone marrow are known to be not cell type specific (12) . Indeed, with this relatively small amount of blood removed over a long period, it is unlikely that the blood loss significantly impacts PMN transit times. In this study, we assume that the effect of blood loss on the bone marrow is similar in all groups. However, we cannot exclude the possibility that statins uniquely impact the bone marrow response to blood loss. Further studies are needed to clarify the effect of statins on the bone marrow response to blood loss.
In summary, chronic exposure to ambient PM 10 in rabbits promotes systemic inflammatory responses characterized by an increase in circulating IL-6. It also stimulates the bone marrow, especially the turnover and release of postmitotic PMNs. Treatment with statins attenuates these responses. Exposure to PM 10 also promotes prolonged retention of PMNs in the lung tissues, reflecting the potential persistent harm of chronic PM 10 exposure. Statins abolish this retention and promote the clearance of retained PMNs from the lung. These inhibitory effects of statins on the bone marrow and lung retention add a new aspect of their anti-inflammatory properties. In this context, statins have attractive qualities for promising applications as therapeutic agents to reduce the adverse health effects of air pollution exposure. 
